Free Trial
Your $100 Credit Expires Tomorrow! Get MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion

Avalyn Pharma (AVLN) 10K Form and Latest SEC Filings 2026

$28.84 +0.43 (+1.51%)
As of 05/22/2026 04:00 PM Eastern

Latest Avalyn Pharma SEC Filings & Recent Activity

Avalyn Pharma (NASDAQ:AVLN) has submitted 39+ documents to the U.S. Securities and Exchange Commission (SEC) since 2023. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13D submitted on May 8, 2026.

Form 4
Avalyn Pharma Inc. Reports Ownership Change on May. 5, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

Avalyn Pharma SEC Filing History

Browse Avalyn Pharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/08/2026 5:52 PM
Avalyn Pharma (1540171) Subject
SUVRETTA CAPITAL MANAGEMENT, LLC (1569064) Filed by
Form SCHEDULE 13D
05/08/2026 3:41 PM
Avalyn Pharma (1540171) Subject
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Filed by
Form SCHEDULE 13D
05/05/2026 9:06 AM
Avalyn Pharma (1540171) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G
05/05/2026 7:37 AM
Avalyn Pharma (1540171) Issuer
FMR LLC (315066) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 5:01 AM
Avalyn Pharma (1540171) Issuer
Golden Adam H. (2130116) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:46 PM
Avalyn Pharma (1540171) Issuer
George Simeon (1595117) Reporting
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:50 PM
Avalyn Pharma (1540171) Issuer
Carroll Jill (1598542) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:25 PM
Avalyn Pharma (1540171) Issuer
Baranowski Lyn (1893640) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:26 PM
Avalyn Pharma (1540171) Issuer
Lavelle Erin (1737613) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:26 PM
Avalyn Pharma (1540171) Issuer
Lazarus Howard (2127626) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:26 PM
Avalyn Pharma (1540171) Issuer
Wellington Biomedical Innovation Master Investors (0) Cayman
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:27 PM
Avalyn Pharma (1540171) Issuer
Haviland Kate (1663022) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:27 PM
Avalyn Pharma (1540171) Issuer
Carlson Douglas R (1640742) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:28 PM
Avalyn Pharma (1540171) Issuer
Rhodes Melissa (2127594) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:29 PM
Avalyn Pharma (1540171) Issuer
Turner Heather D (1403571) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 5:32 PM
Avalyn Pharma (1540171) Issuer
Congleton Jon (1644975) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/30/2026 3:58 PM
Avalyn Pharma (1540171) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
04/29/2026 11:15 PM
Avalyn Pharma (1540171) Filer
Form EFFECT
04/29/2026 8:57 PM
Avalyn Pharma (1540171) Issuer
Wellington Biomedical Innovation Master Investors (0) Cayman
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 7:53 PM
Avalyn Pharma (1540171) Issuer
Novo Holdings A/S (1388325) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 7:44 PM
Avalyn Pharma (1540171) Issuer
FMR LLC (315066) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 6:08 PM
Avalyn Pharma (1540171) Issuer
George Simeon (1595117) Reporting
SR ONE CAPITAL MANAGEMENT, LLC (1853723) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:53 PM
Avalyn Pharma (1540171) Issuer
Carroll Jill (1598542) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:39 PM
Avalyn Pharma (1540171) Issuer
Friedman David Matthew (2108980) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:43 PM
Avalyn Pharma (1540171) Issuer
Congleton Jon (1644975) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:47 PM
Avalyn Pharma (1540171) Issuer
Lavelle Erin (1737613) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:23 PM
Avalyn Pharma (1540171) Issuer
Baranowski Lyn (1893640) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:25 PM
Avalyn Pharma (1540171) Issuer
Carlson Douglas R (1640742) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:26 PM
Avalyn Pharma (1540171) Issuer
Haviland Kate (1663022) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:27 PM
Avalyn Pharma (1540171) Issuer
Lazarus Howard (2127626) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:32 PM
Avalyn Pharma (1540171) Issuer
Turner Heather D (1403571) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:36 PM
Avalyn Pharma (1540171) Issuer
Rhodes Melissa (2127594) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 5:22 PM
Avalyn Pharma (1540171) Issuer
Golden Adam H. (2130116) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/29/2026 1:49 PM
Avalyn Pharma (1540171) Filer
Form CERT
04/29/2026 8:29 AM
Avalyn Pharma (1540171) Filer
Form S-1/A
04/27/2026 3:38 PM
Avalyn Pharma (1540171) Filer
Form 8-A12B
04/23/2026 3:01 PM
Avalyn Pharma (1540171) Filer
Form S-1/A
04/08/2026 3:01 PM
Avalyn Pharma (1540171) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Avalyn Pharma SEC Filings - Frequently Asked Questions

Avalyn Pharma (AVLN) has submitted 39+ filings to the SEC since 2023. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form SCHEDULE 13D submitted on May 8, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:AVLN) was last updated on 5/24/2026 by MarketBeat.com Staff.
From Our Partners